Efpeglenatide - Sanofi

Drug Profile

Efpeglenatide - Sanofi

Alternative Names: HM-11260C; LAPS-Exd4; LAPS-Exendin; LAPS-exendin 4 analogue; LAPS-Exendin4; LAPSCA-Exendin4; SAR-439977

Latest Information Update: 11 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Hanmi Pharmaceutical; Sanofi
  • Class Antihyperglycaemics; Immunoglobulin Fc fragments; Peptides; Polyethylene glycols; Pyrrolidines
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Type 2 diabetes mellitus
  • Phase II Obesity

Most Recent Events

  • 22 Jun 2018 Pharmacodynamics data from a preclinical study in Type-2 diabetes mellitus presented at the 78th Annual Scientific Sessions of the American Diabetes Association (ADA-2018)
  • 27 Apr 2018 Phase-III clinical trials in Type-2 diabetes mellitus in Sweden, Canada (SC) (EudraCT2017-002954-35) (NCT03496298)
  • 27 Apr 2018 Sanofi initiates enrolment in a phase III trial for Type-2 diabetes mellitus in USA (SC) (NCT03496298)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top